During treatment, most gastrointestinal stromal tumors (GIST) will develop secondary mutations in KIT or PDGFRA inducing drug resistance, so there is an unmet need for novel therapies. De Sutter and colleagues tested the efficacy of IDRX-42, a novel specific KIT inhibitor, which showed significant antitumor activity in patient- and cell line-derived GIST xenograft models with volumetric responses, decreased mitotic activity, antiproliferative effects, and characteristic myxoid degeneration. Based on the promising results of this in vivo work, IDRX-42 is currently being investigated in a phase I first-in-human study (NCT05489237) in participants with advanced (metastatic and/or surgically unresectable) GIST.

Radiation-induced sarcomas (RIS) show poor prognosis and lack effective treatment, along with showing increasing incidence globally. Hong and colleagues performed integrative analysis for genomic, transcriptomic, and immunological profile of RISs, revealing that this tumor has higher immune cell infiltration, higher PD-1/PD-L1 expression, and greater neoantigen burden than primary sarcoma. It is proposed that...

You do not currently have access to this content.